Alendronic acid
- Generic Name
- Alendronic acid
- Brand Names
- Adrovance, Binosto, Fosamax, Fosamax Plus D, Fosavance
- Drug Type
- Small Molecule
- Chemical Formula
- C4H13NO7P2
- CAS Number
- 66376-36-1
- Unique Ingredient Identifier
- X1J18R4W8P
- Background
Alendronic acid is a second generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease. It functions by preventing resorption of bone.
- Indication
Alendronic acid is indicated for the treatment and prevention of osteoporosis in men and postmenopausal women, treatment of glucocorticoid-induced osteoporosis, and Paget's disease of bone. However, alendronic acid is not indicated for use in pediatric populations or patients with a creatinine clearance <35mL/min.
- Associated Conditions
- Osteogenesis Imperfecta (OI), Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Paget’s Disease
- Associated Therapies
- -
Treatment of Childhood Osteoporosis With Alendronate (Fosamax)
Phase 2
Completed
- Conditions
- Osteoporosis
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2016-09-22
- Lead Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- Target Recruit Count
- 50
- Registration Number
- NCT00001720
- Locations
- 🇺🇸
National Institute of Child Health and Human Development (NICHD), Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath